Polyarteritis Nodosa: ['A necrotizing vasculitis that affects medium-sized arteries, it is usually idiopathic, and may be triggered by viral infections (Hepatitis B, also others). A multisystem disease, it most commonly affects skin (nodules, livedo reticularis) and peripheral nerves; higher morbidity is associated with gastrointestinal, central nervous system, cardiac, and/or other organ involvement. Anti-neutrophil cytoplasmic antibodies (ANCA) are typically negative. [ NCI ]']
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
90 |
4. Check minimum number of eventsNone |
90 |
5. Include endpointsNone |
90 |
6. Filter based on genotype QC (FinnGen only) |
86 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M30
- Name in latin
- Aliae condiciones polyarteritidi nodosae cognatae
Similar endpoints
↥List of similar endpoints to
Other conditions related to polyarteritis nodosa
based on the number of shared cases.
Similar with more cases:
- Polyarteritis nodosa and related conditions
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 581 | 336 | 240 |
| Only index persons | 484 | 287 | 197 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 64.23 | 64.19 | 64.15 |
| Only index persons | 62.10 | 63.01 | 60.78 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 86 | 55 | 31 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 58.15 | 54.92 | 63.87 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 90
- Matched controls
- 900
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M30.8
ICD-10 Finland
Other conditions related to polyarteritis nodosa
+∞
124.0
88
*
H02AB06
ATC
prednisolone; systemic
16.4
24.0
81
319
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
10.1
23.6
34
51
L04AX01
ATC
azathioprine; systemic
29.8
21.7
29
14
M30.0
ICD-10 Finland
Polyarteritis nodosa
+∞
20.6
19
*
L04AX03
ATC
methotrexate; systemic
8.8
18.3
28
44
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.0
15.6
59
218
M05BA04
ATC
alendronic acid; oral
8.5
15.3
23
35
H02AB07
ATC
prednisone; oral
5.9
11.9
26
58
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.7
11.4
61
277
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
11.5
11.3
21
23
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.3
10.0
38
132
ZX120
NOMESCO Finland
Intravenous
5.3
9.6
23
55
TGC00
NOMESCO Finland
Bronchial lavation
18.7
8.9
13
8
M30.1
ICD-10 Finland
Polyarteritis with lung involvement [Churg-Strauss]
+∞
8.5
8
*
M31.7
ICD-10 Finland
Microscopic polyangiitis
+∞
8.5
8
*
M31.9
ICD-10 Finland
Necrotizing vasculopathy, unspecified
+∞
8.5
8
*
PAW37
NOMESCO Finland
Biopsy of temporal artery
+∞
8.5
8
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.0
8.5
19
29
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.8
8.3
22
57
L04AA06
ATC
mycophenolic acid; systemic
49.4
7.9
9
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
4.0
7.8
28
91
N03AX16
ATC
[U] pregabalin
3.6
7.7
37
147
D69.0
ICD-10 Finland
Allergic purpura
87.0
7.5
8
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
7.9
7.2
16
24
H02AB04
ATC
methylprednisolone; systemic
3.9
7.1
25
80
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.5
7.1
18
33
H02AB09
ATC
hydrocortisone; systemic
13.7
6.8
11
9
Z01.8
ICD-10 Finland
Other specified special examinations
3.6
6.7
28
101
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.7
6.5
16
28
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
74.9
6.5
7
*
M31.8
ICD-10 Finland
Other specified necrotizing vasculopathies
+∞
6.3
6
*
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
+∞
6.3
6
*
SPAT1301
SPAT
No procedures
3.1
6.3
40
185
R03BB04
ATC
tiotropium bromide; inhalant
4.4
6.1
17
45
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.6
6.1
24
82
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
33
16
31.68
24.95
4.0
1.6
242.86
—
titre
—
7
0
24
13
24.62
17.17
8.9
1.3
14.00
—
iu/ml
—
8
0
19
16
14.69
11.49
3.5
1.3
—
—
—
0
0
55
239
4.35
10.74
6.8
2.9
—
—
—
0
0
65
343
4.22
9.13
8.4
8.1
1.21
1.22
mmol/l
0.46
52
300
33
118
3.84
8.11
2.3
1.8
—
—
—
0
0
19
47
4.86
7.52
5.6
5.1
1.23
1.22
mmol/l
0.48
19
42
54
279
3.34
7.26
8.0
3.7
26.01
46.46
ng/l
0.73
43
186
23
69
4.13
7.13
3.2
1.8
246.26
403.17
nmol/l
3.09
23
59
11
10
12.32
6.49
1.3
1.2
—
—
—
0
0
11
10
12.32
6.49
1.2
2.3
—
—
—
0
0
9
5
19.74
6.40
1.8
1.2
—
—
—
0
0
57
321
3.12
6.33
17.7
12.3
1.22
1.22
inr
0.02
25
108
11
11
11.19
6.23
2.2
1.5
—
—
—
0
0
11
11
11.19
6.23
1.8
1.2
—
—
—
0
0
33
140
3.14
5.98
1.7
1.6
1.22
1.07
mg/l
0.20
25
115
11
12
10.25
5.98
1.2
2.1
—
—
—
0
0
11
13
9.46
5.75
1.2
2.0
—
—
—
0
0
38
179
2.94
5.69
3.2
2.7
339.16
7153.97
umol/l
1.06
31
148
10
10
11.07
5.69
1.2
2.0
—
—
—
0
0
39
192
2.82
5.32
7.2
2.7
0.12
0.42
e6/l
1.75
34
150
66
429
3.02
5.23
5.7
5.9
7.01
6.73
mmol/l
0.23
66
401
60
371
2.85
5.23
7.0
3.4
0.00
0.00
estimate
-0.00
28
78
10
14
7.88
4.80
6.7
2.4
61.40
60.86
%
—
10
14
11
18
6.80
4.77
1.5
1.7
—
—
—
0
0
11
18
6.80
4.77
1.5
1.7
—
—
—
0
0
7
5
15.00
4.65
1.3
2.0
—
—
—
0
0
59
376
2.65
4.62
7.1
3.4
0.00
0.00
estimate
-0.00
25
72
41
221
2.57
4.54
6.9
3.5
0.00
0.00
estimate
-0.00
24
68
58
369
2.61
4.52
9.4
4.5
0.00
0.00
estimate
-0.00
25
74
25
105
2.91
4.48
2.0
1.6
29.68
29.19
s
0.19
25
100
22
89
2.95
4.19
2.1
1.6
—
—
—
0
0
7
7
10.70
4.08
1.3
1.4
—
—
—
0
0
26
121
2.62
3.79
1.6
1.2
40.78
49.60
iu/ml
0.14
11
39
8
12
7.19
3.76
1.6
1.8
—
—
—
0
0
25
116
2.60
3.66
1.4
1.2
41.78
24.32
u/ml
—
9
43
8
13
6.63
3.58
1.6
1.6
—
—
—
0
0
19
77
2.86
3.58
4.5
3.4
—
—
—
0
0
15
53
3.20
3.56
2.3
1.6
—
—
—
0
0
6
6
10.59
3.55
1.8
1.7
—
—
—
0
0
11
27
4.49
3.53
1.9
3.0
—
—
—
0
0
6
7
9.07
3.31
1.8
1.6
—
—
—
0
0
10
24
4.55
3.31
1.4
2.5
264.01
455.89
ug/l
—
10
24
20
87
2.67
3.30
2.1
1.5
—
—
—
0
0
12
36
3.68
3.16
3.2
8.1
23.98
25.41
mmol/l
0.80
12
36
8
17
5.05
2.99
1.6
2.8
25.66
25.88
mmol/l
—
8
17
13
47
3.06
2.96
3.5
2.9
72.92
66.92
ng/l
0.11
13
42
11
33
3.65
2.93
2.7
1.4
—
—
—
0
0
5
6
8.72
2.78
1.0
1.2
249.80
251.50
mg/l
—
5
6
7
15
4.96
2.65
2.4
1.7
—
—
—
0
0
5
7
7.47
2.58
1.0
1.0
—
—
—
0
0
5
8
6.53
2.40
1.4
1.0
—
—
—
0
0
5
9
5.81
2.24
2.4
4.7
—
—
—
0
0
43
298
1.85
2.13
7.5
3.5
—
—
—
0
0
6
15
4.20
2.07
1.5
1.4
—
—
—
0
0
6
15
4.20
2.07
1.5
1.4
—
—
—
0
0
17
87
2.18
1.96
2.9
8.5
105.00
104.20
mmol/l
0.39
17
87
8
28
3.03
1.91
1.1
1.0
—
—
—
0
0
5
12
4.34
1.85
1.0
1.8
—
—
—
0
0
5
12
4.34
1.85
1.0
1.8
—
—
—
0
0
5
12
4.34
1.85
1.0
2.0
—
—
—
0
0
8
29
2.93
1.84
1.6
1.3
—
—
—
0
0
31
206
1.77
1.69
8.8
3.8
4.99
10.56
mg/mmol
0.99
24
129
24
148
1.85
1.66
2.4
2.5
—
—
—
0
0
6
20
3.14
1.61
1.2
1.3
—
—
—
0
0
6
21
2.98
1.53
1.7
2.4
134.67
133.73
g/l
—
6
15
19
112
1.88
1.50
7.2
2.6
3.46
3.65
e6/l
0.03
12
69
25
161
1.77
1.50
1.2
1.3
0.57
0.83
u/ml
—
7
39
45
342
1.63
1.46
3.0
2.7
—
—
—
0
0
5
16
3.24
1.46
1.8
1.6
—
—
—
0
0
5
16
3.24
1.46
1.2
1.6
—
—
—
0
0
39
288
1.63
1.41
2.1
1.8
99.50
96.47
pmol/l
0.17
18
134
6
24
2.60
1.32
2.8
2.2
—
—
—
0
0
6
24
2.60
1.32
2.5
2.0
—
—
—
0
0
8
36
2.34
1.28
1.5
1.5
—
—
—
0
0
5
19
2.72
1.23
1.0
1.2
—
—
—
0
0
15
88
1.85
1.20
9.2
7.6
—
—
—
0
0
75
664
1.78
1.20
5.4
4.6
1.97
1.91
mu/l
0.16
69
598
76
682
1.74
1.07
32.2
13.2
82.63
81.22
ml/min/173m2
0.21
70
544
18
119
1.64
0.97
7.3
2.4
0.51
1.09
e6/l
0.67
11
73
12
77
1.64
0.73
2.8
2.3
—
—
—
0
0
53
461
1.36
0.70
4.1
3.0
—
—
—
0
0
10
63
1.66
0.65
3.7
2.5
2.69
1.94
mmol/l
—
10
46
26
206
1.37
0.60
4.7
4.8
2.59
1.91
ug/l
0.66
21
181
53
468
1.32
0.59
4.6
3.0
67.17
49.56
u/l
0.80
48
439
12
83
1.51
0.55
3.5
2.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
72
682
1.28
0.35
4.4
4.0
1.45
1.28
mmol/l
0.99
66
622
17
137
1.30
0.35
1.6
1.5
—
—
—
0
0
6
45
1.36
0.34
3.2
1.9
12.22
12.57
nmol/l
—
6
40
74
704
1.29
0.34
4.6
4.4
1.52
1.49
mmol/l
0.24
67
644
6
46
1.33
0.34
5.0
2.7
667.50
210.37
ng/l
—
6
41
74
707
1.26
0.30
4.7
4.4
4.59
4.64
mmol/l
0.17
69
654
19
163
1.21
0.24
3.6
4.3
19.43
21.04
%
0.19
11
82
0
10
0.00
0.21
0.0
5.7
—
174.47
—
0
10
75
725
1.21
0.21
4.9
4.9
2.59
2.71
mmol/l
0.61
68
666
10
121
0.80
0.19
1.2
1.5
—
—
—
0
0
82
804
1.22
0.14
53.7
20.3
129.74
134.22
g/l
2.68
82
792
22
203
1.11
0.11
1.3
1.7
1.64
1.34
mmol/l
0.35
16
174
72
710
1.07
0.04
5.9
4.5
5.83
5.95
mmol/l
0.27
66
643
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
7.53
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
3.86
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
25.15
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint M13_POYARTOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POYARTOTH | 2.789 [2.0, 3.89] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.129 |
During the follow-up period (1.1.1998 — 31.12.2019), 103 out of 272 females with M13_POYARTOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POYARTOTH | 2.272 [1.53, 3.36] | < 0.001 |
| Birth year | 0.986 [0.97, 1.0] | 0.026 |
During the follow-up period (1.1.1998 — 31.12.2019), 72 out of 194 males with M13_POYARTOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_POYARTOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.244% | 0.365% |
| 5 | 1.567% | 2.344% |
| 10 | 4.319% | 5.549% |
| 15 | 7.846% | 11.556% |
| 20 | 13.131% | 19.031% |
Relationships between endpoints
↥Index endpoint: M13_POYARTOTH – Other conditions related to polyarteritis nodosa
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data